Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease

Pierre J. Blanchet, John Fang, Marjorie Gillespie, Lu Ann Sabounjian, Kenneth W. Locke, Richard Gammans, M Maral Mouradian, Thomas N. Chase

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The contribution of dopamine D1 receptor stimulation to the motor effects of dopaminergic drugs in patients with Parkinson's disease remains undetermined. The authors of this article studied the clinical efficacy, pharmacokinetics, and tolerability of the full D1 receptor agonist dihydrexidine, (±)-trans- 10,11-dihydroxy-5,6,6a,7,8,12-bhexahydrobenzo[a] phenanthridine hydrochloride in a double-blind, placebo-controlled trial in four patients with Parkinson's disease. Single intravenous doses were carefully titrated according to a fixed schedule ranging from 2 mg to the highest tolerated dose (or a maximum of 70 mg) infused over either 15 or 120 minutes. The only patient to achieve a plasma drug concentration greater than 100 ng/ml had a brief but definite motor improvement accompanied by choreic dyskinesias similar to the response to levodopa. Dose-limiting adverse effects, including flushing, hypotension, and tachycardia, were observed in all cases, especially with rapid infusions. No nausea or emesis occurred. Pharmacokinetic studies yielded a plasma half-life <5 minutes. These preliminary data suggest that dihydrexidine has a marginal therapeutic window for providing an antiparkinsonian effect, although it remains uncertain how much of this effect is attributable to pure D1 receptor stimulation.

Original languageEnglish (US)
Pages (from-to)339-343
Number of pages5
JournalClinical Neuropharmacology
Volume21
Issue number6
StatePublished - Nov 1 1998

Fingerprint

Dopamine D1 Receptors
Dopamine Agonists
Parkinson Disease
Phenanthridines
Pharmacokinetics
Antiparkinson Agents
Dopamine Agents
Dyskinesias
Levodopa
Tachycardia
Hypotension
Nausea
Vomiting
Half-Life
Appointments and Schedules
Placebos
Pharmaceutical Preparations
dihydrexidine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Blanchet, P. J., Fang, J., Gillespie, M., Sabounjian, L. A., Locke, K. W., Gammans, R., ... Chase, T. N. (1998). Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology, 21(6), 339-343.
Blanchet, Pierre J. ; Fang, John ; Gillespie, Marjorie ; Sabounjian, Lu Ann ; Locke, Kenneth W. ; Gammans, Richard ; Mouradian, M Maral ; Chase, Thomas N. / Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. In: Clinical Neuropharmacology. 1998 ; Vol. 21, No. 6. pp. 339-343.
@article{786bb45d73524d229d10ac146600ad28,
title = "Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease",
abstract = "The contribution of dopamine D1 receptor stimulation to the motor effects of dopaminergic drugs in patients with Parkinson's disease remains undetermined. The authors of this article studied the clinical efficacy, pharmacokinetics, and tolerability of the full D1 receptor agonist dihydrexidine, (±)-trans- 10,11-dihydroxy-5,6,6a,7,8,12-bhexahydrobenzo[a] phenanthridine hydrochloride in a double-blind, placebo-controlled trial in four patients with Parkinson's disease. Single intravenous doses were carefully titrated according to a fixed schedule ranging from 2 mg to the highest tolerated dose (or a maximum of 70 mg) infused over either 15 or 120 minutes. The only patient to achieve a plasma drug concentration greater than 100 ng/ml had a brief but definite motor improvement accompanied by choreic dyskinesias similar to the response to levodopa. Dose-limiting adverse effects, including flushing, hypotension, and tachycardia, were observed in all cases, especially with rapid infusions. No nausea or emesis occurred. Pharmacokinetic studies yielded a plasma half-life <5 minutes. These preliminary data suggest that dihydrexidine has a marginal therapeutic window for providing an antiparkinsonian effect, although it remains uncertain how much of this effect is attributable to pure D1 receptor stimulation.",
author = "Blanchet, {Pierre J.} and John Fang and Marjorie Gillespie and Sabounjian, {Lu Ann} and Locke, {Kenneth W.} and Richard Gammans and Mouradian, {M Maral} and Chase, {Thomas N.}",
year = "1998",
month = "11",
day = "1",
language = "English (US)",
volume = "21",
pages = "339--343",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Blanchet, PJ, Fang, J, Gillespie, M, Sabounjian, LA, Locke, KW, Gammans, R, Mouradian, MM & Chase, TN 1998, 'Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease', Clinical Neuropharmacology, vol. 21, no. 6, pp. 339-343.

Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. / Blanchet, Pierre J.; Fang, John; Gillespie, Marjorie; Sabounjian, Lu Ann; Locke, Kenneth W.; Gammans, Richard; Mouradian, M Maral; Chase, Thomas N.

In: Clinical Neuropharmacology, Vol. 21, No. 6, 01.11.1998, p. 339-343.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease

AU - Blanchet, Pierre J.

AU - Fang, John

AU - Gillespie, Marjorie

AU - Sabounjian, Lu Ann

AU - Locke, Kenneth W.

AU - Gammans, Richard

AU - Mouradian, M Maral

AU - Chase, Thomas N.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - The contribution of dopamine D1 receptor stimulation to the motor effects of dopaminergic drugs in patients with Parkinson's disease remains undetermined. The authors of this article studied the clinical efficacy, pharmacokinetics, and tolerability of the full D1 receptor agonist dihydrexidine, (±)-trans- 10,11-dihydroxy-5,6,6a,7,8,12-bhexahydrobenzo[a] phenanthridine hydrochloride in a double-blind, placebo-controlled trial in four patients with Parkinson's disease. Single intravenous doses were carefully titrated according to a fixed schedule ranging from 2 mg to the highest tolerated dose (or a maximum of 70 mg) infused over either 15 or 120 minutes. The only patient to achieve a plasma drug concentration greater than 100 ng/ml had a brief but definite motor improvement accompanied by choreic dyskinesias similar to the response to levodopa. Dose-limiting adverse effects, including flushing, hypotension, and tachycardia, were observed in all cases, especially with rapid infusions. No nausea or emesis occurred. Pharmacokinetic studies yielded a plasma half-life <5 minutes. These preliminary data suggest that dihydrexidine has a marginal therapeutic window for providing an antiparkinsonian effect, although it remains uncertain how much of this effect is attributable to pure D1 receptor stimulation.

AB - The contribution of dopamine D1 receptor stimulation to the motor effects of dopaminergic drugs in patients with Parkinson's disease remains undetermined. The authors of this article studied the clinical efficacy, pharmacokinetics, and tolerability of the full D1 receptor agonist dihydrexidine, (±)-trans- 10,11-dihydroxy-5,6,6a,7,8,12-bhexahydrobenzo[a] phenanthridine hydrochloride in a double-blind, placebo-controlled trial in four patients with Parkinson's disease. Single intravenous doses were carefully titrated according to a fixed schedule ranging from 2 mg to the highest tolerated dose (or a maximum of 70 mg) infused over either 15 or 120 minutes. The only patient to achieve a plasma drug concentration greater than 100 ng/ml had a brief but definite motor improvement accompanied by choreic dyskinesias similar to the response to levodopa. Dose-limiting adverse effects, including flushing, hypotension, and tachycardia, were observed in all cases, especially with rapid infusions. No nausea or emesis occurred. Pharmacokinetic studies yielded a plasma half-life <5 minutes. These preliminary data suggest that dihydrexidine has a marginal therapeutic window for providing an antiparkinsonian effect, although it remains uncertain how much of this effect is attributable to pure D1 receptor stimulation.

UR - http://www.scopus.com/inward/record.url?scp=0031726938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031726938&partnerID=8YFLogxK

M3 - Article

C2 - 9844789

AN - SCOPUS:0031726938

VL - 21

SP - 339

EP - 343

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -

Blanchet PJ, Fang J, Gillespie M, Sabounjian LA, Locke KW, Gammans R et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology. 1998 Nov 1;21(6):339-343.